Guanosine‐based multidrug‐loaded codelivery system has demonstrated the ability to suppress typical inflammatory cytokines such as TNF‐α and IL‐6, and ameliorate inflammatory bowel disease through synergistic interactions among its components.[51] Studies previously demonstrated that guanosine demonstrates favorable effects in rats with DNBS‐induced colitis by modulating colonic inflammation and suppressing NF‐κB‐mediated signaling.[52] Consistent with these studies, untargeted metabolomics results demonstrated a significant elevation in guanosine levels following DI supplementation. The gene discussed is NFKB1; the disease is inflammatory bowel disease.